Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 0.72 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | CNR2 | P34972 | 4/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7001985 | 0.85 | KMT2A (0.79) | KMT2AALDH1A1MAPTLMNASLC6A3 | |
| SCHEMBL7003749 | 0.84 | KMT2A (0.77) | KMT2AALDH1A1MAPTLMNASLC6A3 | |
| Flazalone SCHEMBL43716 | 0.84 | KMT2A (1.00) | KMT2AALDH1A1MAPTLMNASLC6A3 | |
| SCHEMBL6998081 | 0.84 | KMT2A (0.77) | KMT2AALDH1A1MAPTLMNASLC6A3 | |
| SCHEMBL6997233 | 0.84 | KMT2A (1.00) | KMT2AALDH1A1MAPTLMNASLC6A3 | |
| SCHEMBL11746033 | 0.83 | KMT2A (0.78) | KMT2AALDH1A1MAPTLMNASLC6A3 | |
| SCHEMBL11746912 | 0.83 | KMT2A (0.70) | KMT2AALDH1A1MAPTLMNASLC6A3 | |
| SCHEMBL11745258 | 0.82 | KMT2A (0.77) | KMT2AALDH1A1MAPTLMNASLC6A3 | |
| SCHEMBL7001736 | 0.82 | KMT2A (0.73) | KMT2AALDH1A1MAPTLMNASLC6A3 | |
| SCHEMBL7001994 | 0.81 | KMT2A (0.68) | KMT2AALDH1A1MAPTLMNASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090035784-A1 | NPC1L1 AND NPC1L1 INHIBITORS AND METHODS OF USE THEREOF | MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY (US) | 2009-02-05 | — | — | US | disclosed |
| US-20090035784-A1 | NPC1L1 AND NPC1L1 INHIBITORS AND METHODS OF USE THEREOF | MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY (US) | 2009-02-05 | — | — | US | disclosed |
| EP-1242080-A4 | DOPAMINE TRANSPORTER INHIBITORS AND THEIR USE | UNIV GEORGETOWN (US) | 2003-01-22 | — | — | EP | disclosed |
| EP-1242080-A1 | DOPAMINE TRANSPORTER INHIBITORS AND THEIR USE | GEORGETOWN UNIVERSITY (US) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001022964-A1 | DOPAMINE TRANSPORTER INHIBITORS AND THEIR USE | GEORGETOWN UNIVERSITY (US) | 2001-04-05 | — | — | WO | disclosed |
| US-4022786-A | PHARMACEUTICALS, CNS STIMULANT | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DT) | 1977-05-10 | — | — | US | disclosed |
| US-4016280-A | 4,4-Diarylpiperidine compositions and use | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DT) | 1977-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090035784-A1 | NPC1L1 AND NPC1L1 INHIBITORS AND METHODS OF USE THEREOF | NPC1L1, NPC1, SREBF2 | KMT2A 2336/4885ALDH1A1 1980/4885MAPT 1822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.